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Necrotic cells release HMGB1 as a danger signal to activate the immune system. In this issue of Immunity,
Kazama et al. (2008) identify a mechanism that determines whether HMGB1 is tolerogenic or immunogenic.One of the most puzzling and fascinating
questions in immunology is how the im-
mune system senses that the body is
under attack by pathogens and how it
decides to unleash its arsenal of defense
mechanisms. An incorrect decision can
have devastating consequences—shock
in the short term or autoimmunity in the
long term. Many pathogens contain or
produce pathogen-associated molecular
patterns (PAMPs), such as lipopolysac-
charide (LPS), bacterial DNA, or viral
RNA, that can trigger an anti-pathogen re-
sponse by binding to pattern-recognition
receptors (PRRs). However, the immune
system can also detect the manner in
which cells die, either through a ‘‘forced’’
form of cell death (necrosis) or a physio-
logical form of cell death (apoptosis).
Billions of immune cells die every day by
apoptosis without eliciting an immune re-
sponse. Apoptotic cell death is viewed by
the immune system as tolerogenic. In
recent years it has been recognized
that the immune system can respond to
both PAMPs and endogenous danger sig-
nals generally termed damage-associ-
ated molecular patterns (DAMPs). Den-
dritic cells (DCs) are the most efficient
and potent antigen-presenting cells. DCs
require activation to properly function in
initiating an immune response. Almost
10 years ago, Polly Matzinger showed
that DCs can be activated by endogenous
‘‘danger’’ signals that are provided by
cells that are stressed, virally infected, or
are necrotic (Gallucci et al., 1999). In
contrast, healthy cells, or those dying by
apoptosis, failed to fully activate DCs. A
number of danger signals have since
been identified. These include high-mo-
bility group (HMG) protein B1, heat-shock
proteins, and uric acid crystals. A paper in
this issue of Immunity focuses on HMGB1
as a central marker for cells that need to
elicit an immunogenic response versus
cells that need to be tolerogenic (Kazamaet al., 2008). In contrast to prior sugges-
tions, the authors find that the regulation
lies not simply in the release of HMGB1
from necrotic cells, but rather in the oxida-
tive state of the HMGB1 that is released.
HMGB1 is an abundant nuclear protein
tightly associated with chromatin and
serves both as a transcription factor and
as an inflammatory cytokine (Bianchi
and Manfredi, 2007). HMGB1 binds to
two receptor systems, Toll-like receptors
(TLRs) 2, 4, and 9 and RAGE (receptor
for advanced glycation end-products).
HMGB1 is released by necrotic cells and
by apoptotic tumor cells when they are
killed by NK or T cells. Although initially it
was believed that the release of HMGB1
from the nucleus either to the cytosol or
to the extracellular space was sufficient
to distinguish necrotic from apoptotic cells
(Scaffidi et al., 2002), it was later demon-
strated that apoptotic tumor cells can
also be immunogenic (Tesniere et al.,
2008). In addition, it was shown that cer-
tain apoptotic cells release HMGB1 (Bell
et al., 2006). It was, therefore, postulated
that a posttranslational modification of
HMGB1 was responsible for its different
activities (Bianchi and Manfredi, 2007).
Apoptosis, in contrast to classical ne-
crosis, is a very organized process that
culminates in the activation of a set of
cysteine proteases, the caspases. In the
intrinsic apoptosis pathway, mitochondria
are key. During apoptosis they lose their
transmembrane potential (DJm). Mito-
chondrial outer-membrane permeabiliza-
tion (MOMP) results in release of multiple
apoptogenic factors, most notably cyto-
chrome c, which cause the activation of
caspase-9 and the executioner caspases
3 and 7 (Figure 1). These caspases then
cleave various intracellular substrates
that in turn cause the typical changes,
such as membrane blebbing or DNA frag-
mentation, that are observed in apoptotic
cells. Caspase activation, although notImmunessential for apoptosis induction, is nev-
ertheless a hallmark of apoptotic cells
when it occurs.
Kazama and coworkers based their
study on two observations: First, blocking
caspase activity turns a tolerogenic signal
into an immunogenic one (Ferguson et al.,
2002), and second, blocking MOMP by
overexpression of Bcl-xL prevents toler-
ance induction by lymphocytes that are
undergoing apoptosis through the type I
Fas pathway (Griffith et al., 1996). These
observations pointed to a role for cas-
pases in altering a mitochondrial function
that might be important for the tolerogenic
effect of apoptotic cells on the immune
system.
To test the difference between the
effects of apoptotic and necrotic cells on
the adaptive immunological response,
Kazama and coworkers employed a clas-
sical system involving intravenous injec-
tion of either hapten-modified cells or
cells fed to hapten-modified DCs. To
assess immunogenicity, they challenged
mice in the footpad with antigen 5 days
after injection of cells. To assess toleroge-
nicity, they immunized mice subcutane-
ously with the antigen on day 2 and
then challenged them with antigen after
4 days. Footpad swelling was taken as
a measure of delayed-type hypersensitiv-
ity. By feeding normal or caspase-3- and
caspase-9-deficient mouse embryonic
fibroblasts induced to undergo cell death
by UV radiation to the DCs, the authors
showed that only the cells deficient in
caspase expression were immunogenic.
Subsequent experiments confirmed that
the lack of caspases converted tolero-
genic cells into immunogenic cells.
Kazama and coworkers also found that
they could effectively prevent tolerance
induction by treating apoptosing spleno-
cytes with a reactive oxygen species
(ROS) scavenger, suggesting that cas-
pase-induced ROS could be involved inity 29, July 18, 2008 ª2008 Elsevier Inc. 1
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Previewsthe effect. They confirmed the role of ROS
by demonstrating that treatment of apo-
ptosing cells with the reducing agent
dithiothreitol destroyed the cells’ ability
to induce tolerance; from the reverse per-
spective, H2O2 treatment of splenocytes
made necrotic by freeze-thawing made
them tolerogenic. These data, which the
authors confirmed by using ovalbumin as
an antigen, suggested that a molecule in
the dying cells was the target of oxidation.
The group led by Doug Green previ-
ously showed that during apoptosis the
75 kDa subunit of the respiratory complex
I, NDUFS1, is cleaved by executioner
caspases, resulting in reduced ability to
lose DJm and ATP levels and, most im-
portantly, to produce ROS (Ricci et al.,
2004). This work established a molecular
link between caspase-dependent apo-
ptosis and ROS production. On the basis
of these data linking caspases to ROS
production via cleavage of NDUFS1, cells
expressing a mutant p75 resistant to cas-
pase cleavage were tested. UV-irradiated
HeLa cells apoptosed with the same ki-
netics as cells expressing wild-type p75
and were also engulfed by DCs at a similar
rate. However, DCs fed with HeLa cells
expressing the mutant protein failed to
induce tolerance, pointing to p75 as the
caspase target that renders apoptotic
cells tolerogenic. One of the clearest dif-
ferences between apoptotic and necrotic
cells is that the latter release HMGB1.2 Immunity 29, July 18, 2008 ª2008 ElsevierHowever, when the supernatants from
apoptotic and from necrotic HeLa cells
were tested, HMGB1 was found to be se-
creted in similar quantities—a result that,
at first glance, almost excluded HMGB1
as the mediator of the dramatic differ-
ences in immunogenicity between the
two cell preparations. However, depletion
of HMGB1 from the supernatant of the ne-
crotic cells, or use of necrotic cells from
HMGB1-deficient mice, caused the cells
to lose their ability to induce an immune
response. Importantly, supplementing
the cells with HMGB1-containing super-
natant from apoptotic cells did not restore
immunogenicity. These results suggested
that it was not merely the presence but,
rather, the quality of HMGB1 that was dif-
ferent between apoptotic and necrotic
cells.
It has previously been suggested that
the activity of HMGB1 as an activator of
the immune system is regulated by post-
translational modifications. The modifica-
tions that were discussed in this context
were acetylation, methylation, and phos-
phorylation. In particular, hyperacetylated
HMGB1, as isolated from actively secret-
ing immune cells, was suggested to
be more active as an adjuvant than puri-
fied recombinant protein (Bianchi and
Manfredi, 2007). However, in light of the
difference in ROS production between
p75-mutant- and p75-wild-type-express-
ing cells undergoing apoptosis, it wasInc.a logical next step to test whether
HMGB1 could be a sensor of oxidative
stress, and indeed, that has been reported
(Hoppe et al., 2006). The authors went on
to demonstrate that, of the three cysteine
residues in HMGB1, the oxidation of
Cys106 alone was sufficient to block
the immunogenic activity of HMGB1
(Figure 1).
Interestingly, although HMGB1 was
found to be important for the activation
of DCs, it did not significantly affect their
maturation, leaving open the question as
to how HMGB1 affects the activity of
DCs. It will also be interesting to deter-
mine how the different forms of HMGB1
affect other cell types, such as macro-
phages, and how different forms of
HGMB1 regulate innate immunological
functions. Another important question
raised by the work of Kazama et al.
(2008) is how DCs recognize the differ-
ence between oxidized and nonoxidized
HMGB1—what receptors are utilized
and what signaling pathways are being
activated. This knowledge could poten-
tially be used to modulating DC activities
and interfering with unwanted immuno-
logical activation.
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(2008). Cell Death Differ. 15, 3–12.Figure 1. Oxidation of HMGB1 Prevents It from Being Immunogenic
(Left) In necrotic cells, HMGB1 is released from dying cells possessing full immunogenic activity. Binding
of HMGB1 to RAGE and/or TLRs induces activation and/or maturation of DCs.
(Right). In contrast, in cells undergoing apoptosis, activated caspase-3 and caspase-7 cleave the complex
I component p75 NDUFS1 and thus halt the respiratory chain, leading to production of ROS, which oxidize
cysteine 106 in HMGB1. This modified protein cannot fully activate DCs and has tolerogenic activities.
DC, dendritic cell.
